Company Overview

Tactile Systems Technology, Inc. (NASDAQ: TCMD) is a U.S.-based medical technology company focused on developing and commercializing medical devices for the treatment of chronic diseases at home. The company primarily operates in the healthcare and durable medical equipment industries, with a focus on lymphatic and respiratory therapies. Its core products are designed to help manage chronic swelling conditions such as lymphedema and chronic venous insufficiency, as well as pulmonary conditions requiring airway clearance therapy. The company generates most of its revenue through direct sales and reimbursement-supported device prescriptions in the United States healthcare market.

The company’s principal business lines include the Compression Therapy segment and the Airway Clearance segment. Its flagship products include the Flexitouch system for lymphedema treatment, the Entre system for venous and lymphatic conditions, and the AffloVest respiratory therapy product. Tactile Systems primarily serves patients, physicians, hospitals, outpatient clinics, and integrated healthcare providers. The company was founded in 1995 and evolved from a specialty medical device developer into a focused chronic-care therapy provider with a direct-to-patient distribution model and reimbursement expertise that differentiates it within the home medical technology sector.

Business Operations

Tactile Systems conducts operations primarily through two reportable segments: Compression Therapy and Airway Clearance. The Compression Therapy business generates the majority of company revenue through advanced pneumatic compression devices prescribed for lymphedema and chronic venous disorders. The Airway Clearance business centers on high-frequency chest wall oscillation therapy products used by patients with chronic pulmonary conditions. Revenue is primarily generated through direct sales supported by insurance reimbursement programs, including Medicare, Medicaid, Veterans Affairs programs, and commercial insurers.

The company’s operations are concentrated in the United States, where it maintains a direct sales force, reimbursement support infrastructure, and clinical education capabilities. Tactile Systems controls proprietary therapy platforms, software-enabled device technologies, and patient support systems designed for in-home use. A notable acquisition was RespirTech, which added the AffloVest airway clearance platform and expanded the company into respiratory care. The company also maintains relationships with healthcare systems, prescribing physicians, and payer organizations that support patient onboarding and reimbursement processing.

Strategic Position & Investments

Tactile Systems has positioned itself as a specialized provider of home-based chronic disease management therapies. Its strategy has emphasized expanding clinical adoption of pneumatic compression therapy, increasing penetration within underserved lymphedema patient populations, and broadening reimbursement coverage through clinical evidence generation. The company has invested in sales force expansion, physician education, and patient engagement initiatives aimed at increasing awareness of chronic lymphatic and pulmonary conditions.

The acquisition of RespirTech represented a major strategic investment that diversified the company beyond compression therapy into airway clearance technologies. Tactile Systems has also invested in clinical studies and health-economic data intended to demonstrate improved patient outcomes and reduced healthcare utilization associated with home therapy. Emerging strategic priorities identified in public filings and investor communications include digital patient engagement capabilities, operational efficiency initiatives, and expansion of referral relationships with integrated delivery networks and veterans’ healthcare systems.

Geographic Footprint

Tactile Systems is headquartered in Minneapolis, Minnesota, and its operations are predominantly concentrated in the United States. The company serves patients across multiple U.S. regions through a nationwide direct sales and clinical support infrastructure. Its principal market exposure remains domestic due to the reimbursement-driven nature of its business model and the regulatory alignment of its products with the U.S. healthcare system.

Although the company’s commercial activities are largely U.S.-focused, its products and supply chain activities involve broader international manufacturing and sourcing relationships. Public disclosures indicate limited direct international revenue contribution relative to domestic operations. Data regarding significant independent international operating divisions or material overseas market penetration is inconclusive based on available public sources.

Leadership & Governance

Tactile Systems is led by an executive team with backgrounds in medical devices, healthcare operations, reimbursement management, and commercial strategy. The company’s governance structure includes an independent board of directors and management oversight aligned with public-company reporting standards under SEC filings and Nasdaq corporate governance requirements. Leadership strategy has emphasized patient-centered care delivery, evidence-based commercialization, and disciplined operational execution within specialized chronic-care markets.

Key executives include:

• Sheri Dodd – President and Chief Executive Officer
• Elaine M. Birkemeyer – Chief Financial Officer
• Adam J. Jaffe – Chief Legal Officer and Corporate Secretary
• Kristie Burns – Chief Human Resources Officer
• Nick L. Perkins – Chief Commercial Officer

Public statements from company leadership have consistently emphasized expanding patient access, strengthening reimbursement pathways, and increasing clinical adoption of home-based therapy solutions as central components of the company’s long-term strategic vision.